Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Rongshu is an osmotic laxative combination developed by Yangtze River Pharmaceutical Group, primarily indicated for the treatment of functional constipation and for bowel cleansing prior to clinical procedures such as colonoscopy or surgery. The formulation consists of polyethylene glycol (PEG) 4000, a high-molecular-weight linear polymer, along with essential electrolytes including sodium chloride, sodium bicarbonate, and potassium chloride. PEG 4000 works by binding water molecules through hydrogen bonding, thereby increasing the osmotic pressure and water content within the intestinal lumen. This leads to an increase in fecal volume, softening of the stool, and stimulation of colonic motility. The inclusion of electrolytes is designed to maintain the body's water-electrolyte balance, minimizing the risk of dehydration or electrolyte disturbances during the purgative process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 4000 + sodium chloride + sodium bicarbonate + potassium chloride.